How orphan designated drugs private equity performed in the pharmaceutical industry in Q2 2023

In value terms, orphan designated drugs-related deal activity increased by 2248% in Q2 2023 compared with the previous quarter’s total of $22.8m and fell by 56% as compared to Q2 2022. Related deal volume increased by 133% in Q2 2023 versus the previous quarter and was 42% lower than in Q2 2022.

The top-ranked legal advisors supporting these private equity deals in Q2 2023 were Goodwin Procter; Latham & Watkins; Lefevre Pelletier & associes, Avocats with 1, 1, 1 deals respectively.

For further understanding of GlobalData’s New Drug Approvals and Their Contract Manufacture – 2023 Edition buy the report here.

This content was updated on 18 July 2023

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Deals Database tracks global deal activity, including mergers, acquisitions, capital raising, strategic alliances, and licensing agreements. Proprietary analysis is used to group deals into key thematic areas and granular sectors across the world’s largest industries.

This analysis considers only announced and completed deals from the GlobalData financial deals database and excludes all terminated and rumoured deals. Deal type includes Buyouts and Direct Investments done by Private Equity firms.

Anumana Receives FDA Clearance for ECG-AI Algorithm to Detect Low Ejection Fraction

What You Should Know: Today, Anumana, a nference portfolio company working in collaboration with Mayo Clinic, announced it has received its first 510(k) clearance from the U.S. FDA for

October 2, 2023

Canopy Growth Has Gone From Hero to Potential Zero

You’re reading a copy of this week’s edition of the New Cannabis Ventures weekly newsletter, which we have been publishing since October 2015. The newsletter

July 17, 2023

Scientists discover feedback loop that controls itch and inflammation

It can be a relief to scratch the occasional itch, but when itch gets out of control, it can become a serious health problem. How

October 14, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.